Medtronic's next-gen renal denervation catheter and procedure are in the works to advance the FDA-approved Symplicity Spyral ...
The global cardiovascular devices market, valued at US$72.83 billion in 2023, is forecasted to grow at a robust CAGR of 7.3%, ...
GlobalData on MSN2d
Stereotaxis wins European approval for robotic ablation catheterStereotaxis has won European CE mark approval for its MaGiC ablation catheter, a robotically navigated device for the ...
Nothing doctors prescribed controlled Michael Garrity’s dangerously high blood pressure — until they zapped away some nerves ...
Every year, a health care think tank called the Lown Institute ranks the 10 worst examples of "profiteering and dysfunction" ...
The Associated Press on MSN6d
Keeping blood pressure under control is critical. There’s a new option for tough casesNothing doctors prescribed controlled Michael Garrity’s dangerously high blood pressure — until they zapped away some nerves ...
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...
In 2023, the catheter market is projected to surge to a size of around USD 12,591.30 million. In the forecast period from ...
Strategies aimed at improving catheter deliverability and increasing CVR may increase ... Stryker, Cerenovus, Acandis and Medtronic outside the submitted work. JF: personal fees from Consultant for ...
Medtronic is a solid dividend-paying stock. Its stock recently yielded 3.2%. It has increased its payout for nearly 50 years in a row. If you're a dividend investor, I can understand why ...
Stereotaxis said today that it has secured CE mark approval for its Magic robotically-navigated magnetic ablation catheter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback